Citius Pharmaceuticals Inc's Business Segments

The Company was formed in the state of Nevada on September 9, 2010 as Trail One, Inc. On September 12, 2014, we entered into a Share Exchange and Reorganization Agreement (the "Exchange Agreement"), among Trail One, Inc., Citius Pharmaceuticals, LLC, a Massachusetts limited liability company ("Citius"), and the beneficial holders of the membership interests of Citius (the "Citius Stockholders"). On September 12, 2014, Trail One, Inc. had no assets, no liabilities, and 5,000,000 shares of issued and outstanding common stock.

Pursuant to the Exchange Agreement, (i) Trail One, Inc. issued 21,625,219 shares of common stock to the Citius Stockholders, which represented approximately 72.0% of the outstanding shares of common stock following the closing of the Exchange Agreement (the "Reverse Acquisition") and the first closing of the Private Offering described below. The Trail One, Inc. existing shareholders before the Reverse Acquisition and the first closing of the Private Offering owned 5,000,000 shares of common stock or 16.7% of the outstanding shares of common stock following the closing of the Exchange Agreement.

Citius Pharmaceuticals Inc. is focused on the development and commercialization of innovative therapeutics, particularly in the area of critical care, with an emphasis on delivering advanced medications that improve patient outcomes. Below are the key segments, products, and services offered by Citius Pharmaceuticals:

Segments

1. Critical Care Therapeutics:
- Citius focuses on developing treatments for patients in critical conditions where existing therapies may have limitations. Their approach is often geared towards enhancing the accessibility and efficacy of therapeutic regimens.

2. Pain Management:
- The company is engaged in developing products aimed at pain management, especially in acute care settings. This segment typically centers on maximizing patient comfort while minimizing side effects.

3. Infectious Diseases:
- Citius also explores products aimed at combating infections, particularly in patients who are immunocompromised or in critical conditions where conventional antibiotic treatments may prove inadequate.

4. Regenerative Medicine:
- Though less emphasized, there is an interest in therapies that promote healing and recovery through innovative regenerative approaches.

Products

1. Hydrocortisone and Lidocaine Formulations:
- Citius has recently concluded a double-blind placebo-controlled Phase 2 study testing six different formulations of hydrocortisone and lidocaine at various strengths. These formulations aim to improve pain management significantly while also addressing inflammation in acute care settings.

2. Acute Care Therapeutic Additives:
- The company is exploring combinations of existing drugs to enhance therapeutic outcomes for acute patients, potentially resulting in products that can provide multifaceted treatment strategies.

3. Branded Generics:
- While focused on innovative medications, Citius also acknowledges the potential of branded generics, particularly those that can fulfill unmet medical needs in pain management and acute therapies.

Services

1. Clinical Development Expertise:
- The firm is equipped with a team of professionals who specialize in navigating the complex landscape of clinical trials. Their service includes designing and conducting rigorous clinical studies, such as the Phase 2b and Phase 3 trials alongside supporting studies.

2. Regulatory Strategy and Support:
- Citius provides comprehensive support services that assist in navigating the regulatory environment, particularly in engaging with the FDA and preparing for New Drug Applications (NDAs).

3. Market Access Analysis:
- Understanding market dynamics and positioning products effectively is key. Citius aims to identify strategies for optimal market entry post-approval, facilitating access to healthcare providers and patients.

4. Collaboration and Partnership Opportunities:
- The company actively seeks partnerships with organizations that aim to enhance patient care. This strategy includes negotiations for co-promotion of products, licensing, and acquiring innovative developments in pharmaceuticals.

Future Studies and Development Strategy

- Following the completion of their Phase 2 study, Citius Pharmaceuticals is poised to move direction towards Phase 2b and subsequently Phase 3 trials. The Phase 2b study will focus on assessing the contribution of the combined hydrocortisone and lidocaine formulation’s efficacy, potentially involving around 400 patients and costing approximately $4 million. If successful, a Phase 3 study with up to 800 patients will follow, with an estimated duration of 18 months and a cost of around $8 million.

- Citius anticipates conducting several supporting studies concurrently with the Phase 3 trial. The outcome of these studies, along with a successful Phase 3 result, would ultimately guide them towards filing a New Drug Application, aiming for completion within three to four years post-trial.

By engaging in these extensive and methodical development efforts, Citius Pharmaceuticals is dedicated to addressing significant healthcare challenges and supporting improved patient outcomes in critical care settings.